Cevimeline 

Cevimeline
Systematic (IUPAC) name
2-methyspiro(1,3-oxathiolane-5,3)quinuclidine
Identifiers
CAS number 107233-08-9
ATC code  ?
PubChem 83898
DrugBank APRD00224
Chemical data
Formula C10H17NOS 
Mol. mass 489.565 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding < 20%
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

C
Legal status

Rx only
Routes Oral

Cevimeline is a parasympathomimetic and muscarinic agonist,1 with particular effect on M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.

Contents

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping. 2

References

  1. ^ Ono M, Takamura E, Shinozaki K, et al (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277, http://linkinghub.elsevier.com/retrieve/pii/S0002939404001369. 
  2. ^ [1] MedicineNet: Cevimeline. Accessed 10/12/2007

External links

v • d • e
Parasympathomimetics / cholinergic agonists / acetylcholinesterase inhibitors (N06DA, N07AA)
Direct
(at receptor)
Indirect/AIs
(in synapse)